The occurrence of diarrhea not related to the pharmacokinetics of MPA and its metabolites in liver transplant patients

European Journal of Clinical Pharmacology

Volumn 66, Issue 7, 2010, Pages 671-679

  Xia, Zhang Wei ^a   Jun, Chen Yong ^a   Hao, Chen ^a   Bing, Chen ^a   Min, Shi Min ^a   Jie, Xie Jun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acyl glucuronide; Diarrhea; Liver transplantation; Mycophenolic acid

Indexed keywords

BASILIXIMAB; DRUG METABOLITE; IMMUNOMODULATING AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID ACYL GLUCURONIDE; MYCOPHENOLIC ACID BETA D GLUCURONIDE; PREDNISONE; TACROLIMUS; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; FEMALE; GRAFT RECIPIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DRUG COMBINATION; MIDDLE AGED;

ADULT; AGED; AREA UNDER CURVE; DIARRHEA; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 77955565408     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0833-2     Document Type: Article

References (50)

1. Wong NA, Bathgate AJ, Bellamy CO (2002) Colorectal disease in liver allograft recipients-a clinicopathological study with followup. Eur J Gastroenterol Hepatol 14:231-236
2. Knoll GA, MacDonald I, Khan A, Van Walraven C (2003) Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 14:2381-2386
3. European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345:1321-1325
4. Pelletier RP, Akin B, Henry ML, Bumgardner GL, Elkhammas EA, Rajab A, Ferguson RM (2003) The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 17:200-205
5. Cantarovich M, Tzimas GN, Barkun J, Deschênes M, Alpert E, Tchervenkov J (2003) Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term livertransplant patients with renal dysfunction. Transplantation 76: 98-102
6. Koch RO, Graziadei IW, Schulz F, Nachbaur K, Königsrainer A, Margreiter R, Vogel W (2004) Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transplant Int 7:518-524 (Pubitemid 39592738)
7. Bailey MJ, Dickinson RG (2003) Acyl glucuronide reactivity in perspective: biological consequences. Chem Biol Interact 145:117-137
8. Shipkova M, Armstrong VW, Oellerich M, Wieland E (2005) Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol 1:505-526
9. Budde K, Curtis J, Knoll G, Wieland E (2004) Enteric-coated mycophenolate sodium can be safely administered in maintenancerenal transplant patients: results of a 1-year study. Am J Transplant 4:237-243
10. Shipkova M, Armstrong VW, Wieland E, Niedmann PD, Schütz E, Brenner-Weiss G, Voihsel M, Braun F, Oellerich M (1999) Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 126:1075-1082 (Pubitemid 29123740)
11. Kuypers DR, Vanrenterghem Y, Squifflet JP, Mourad M, Abramowicz D, Oellerich M, Armstrong V, Shipkova M, Daems J (2003) Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 25:609-622
12. Shipkova M, Armstrong VW, Weber L, Niedmann PD, Wieland E, Haley J, Tönshoff B, Oellerich M, German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients (2002) Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 24:390-399
13. Treinen-Moslen M, Kanz MF (2006) Intestinal tract injury by drugs: importance of metabolite delivery by yellow bile road. Pharmacol Ther 112:649-667
14. Kamar N, Faure P, Dupuis E, Cointault O, Joseph-Hein K, Durand D, Moreau J, Rostaing L (2004) Villous atrophy induced by mycophenolate mofetil in renal-transplant patients. Transpl Int17:463-467
15. Heller T, van Gelder T, Budde K, de Fijter JW, Kuypers D, Arns W, Schmidt J, Rostaing L, Powis SH, Claesson K, Macphee IA, Pohanka E, Engelmayer J, Brandhorst G, Oellerich M, ArmstrongVW (2007) Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am J Transplant 7:1822-1831
16. Chen B, Zhang WX, Yu ZC, Cai WM (2007) Determination of mycophenolic acid (MPA) and its acyl and phenol glucuronide metabolites simultaneously in human plasma by a simplified HPLC method. Anal Lett 40:2465-2475
17. Chen H, Peng C, Yu Z, Shen B, Deng X, Qiu W, Fei Y, Shen C, Zhou G, Yang W, Li H (2007) Pharmacokinetics of mycophenolicacid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. Clin Pharmacokinet 46:175-185
18. Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, McMaster P, Kalayoglu M, Levy G, Freeman R, Bismuth H, Neuhaus P, Mamelok R, Wang W (2001) A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 7:442-450
19. Pfitzmann R, Klupp J, Langrehr JM, Uhl M, Neuhaus R, Settmacher U, Steinmüller T, Neuhaus P (2003) Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation 76:130-136
20. Fairbanks KD, Thuluvath PJ (2004) Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transplant 10:1189-1194
21. Moreno JM, Rubio E, Gómez A, Lopez-Monclus J, Herreros A, Revilla J, Navarrete E, Sánchez Turrin V, Jimenez M, Cuervas- Mons V (2003) Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. Transplant Proc 35:1874-1876 (Pubitemid 37093747)
22. Moreno Planas JM, Cuervas-Mons Martinez V, Rubio Gonzalez E, Gomez Cruz A, Lopez-Monclus J, Sánchez-Turrion V, Lucena Poza JL, Jimenez Garrido M, Millan I (2004) Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 4:1650-1655
23. Maes BD, Vanwalleghem J, Kuypers D, Ghoos Y, Rutgeerts PJ, Vanrenterghem YF (1999) Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. Transplantation 68:1482-1485
24. Hale MD, Nicholls AJ, Bullingham RE, Hené R, Hoitsma A, Squifflet JP, Weimar W, Vanrenterghem Y, Van de Woude FJ, Verpooten GA (1998) The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation.Clin Pharmacol Ther 64:672-683 (Pubitemid 29011387)
25. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS (1997) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppressionafter cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63:977-983
26. Flechner SM, Feng J, Mastroianni B, Savas K, Arnovitz J, Moneim H, Modlin CS, Goldfarb D, Cook DJ, Novick AC (2005) The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation 79:926-934
27. Borrows R, Chusney G, Loucaidou M, James A, Lee J, Tromp JV, Owen J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, Taube D (2006) Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 6:121-128
28. Tredger JM, Brown NW, Adams J, Gonde CE, Dhawan A, Rela M, Heaton N (2004) Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transplant 10:492-502
29. Hao C, Anwei M, Bing C, Baiyong S, Weixia Z, Chuan S, Erzhen C, Xiaxing D, Weihua Q, Weiping Y, Chenghong P, Hongwei L (2008) Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia. Liver Transplant 14:1165-1173
30. Bullingham RES, Nicholls A, Hale M (1996) Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 28:925-929
31. Sugioka N, Sasaki T, Kokuhu T, Ito Y, Shibata N, Okamoto M, Yoshimura N, Takada K (2006) Clinical pharmacokinetics of mycophenolate mofetil in Japanese renal transplant recipients: a retrospective cohort study in a single center. Biol Pharm Bull 29:2099-2105
32. Arns W (2007) Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? Transplant Proc 39:88-93
33. Shipkova M, Armstrong VW, Oellerich M, Wieland E (2003) Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25:1-16
34. Wieland E, Shipkova M, Schellhaas U, Schütz E, Niedmann PD, Armstrong VW, Oellerich M (2000) Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 33:107-113
35. Maes B, Oellerich M, Ceuppens JL, Armstrong VW, Evenepoel P, Kuypers D, Messiaen T, Shipkova M, Wieland E, Vanrenterghem Y (2002) A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. Nephrol Dial Transplant 17:923-926
36. Shipkova M, Strassburg CP, Braun F, Streit F, Gröne HJ, Armstrong VW, Tukey RH, Oellerich M, Wieland E (2001) Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 132:1027-1034
37. Schütz E, Shipkova M, Armstrong VW, Wieland E, Oellerich M (1999) Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 45:419-422 (Pubitemid 29114183)
38. European FK506 Multicentre Liver Study Group (1994) Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 344:423-428
39. U.S. Multicenter FK506 Liver Study Group (1994) A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med 331:1110-1115
40. Ducloux D, Ottignon Y, Semhoun-Ducloux S, Labbé S, Saint- Hillier Y, Miguet JP, Carayon P, Chalopin JM (1998) Mycophenolate mofetil-induced villous atrophy. Transplantation 66: 1115-1116
41. Maes B, Dalle I, Geboes K, Oellerich M, Armstrong VW, Evenepoel P, Geypens B, Kuypers D, Shipkova M, Geboes K, Vanrenterghem YF (2003) Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation 75:665-672
42. Shipkova M, Spielbauer B, Voland A, Gröne HJ, Armstrong VW, Oellerich M, Wieland E (2004) cDNA microarray analysis reveals new candidate genes possibly linked to side effects under mycophenolate mofetil therapy. Transplantation 78:1145-1152
43. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y (2006) Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82:1074-1084
44. Satoh S, Tada H, Murakami M, Tsuchiya N, Li Z, Numakura K, Saito M, Inoue T, Miura M, Hayase Y, Suzuki T, Habuchi T (2006) Circadian pharmacokinetics of mycophenolic acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation 82:486-493
45. Picard N, Cresteil T, Premaud A, Marquet P (2004) Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4 / 5. Ther Drug Monit 26:600-608
46. Strassburg CP, Barut A, Obermayer-Straub P, Li Q, Nguyen N, Tukey RH, Manns MP (2001) Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7. J Hepatol 34:865-872
47. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J (1999) Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 21:35-43
48. Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, Miura M, Suzuki T, Kato T, Habuchi T (2005) Impact of CYP3A5 and MDR1(ABCB1)C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 37:1730-1732
49. Sawyer MB, Innocenti F, Das S, Cheng C, Ramírez J, Pantle- Fisher FH, Wright C, Badner J, Pei D, Boyett JM, Cook E Jr, Ratain MJ (2003) A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 73:566-574.
50. van Agteren M, Armstrong VW, van Schaik RH, de Fijter H, Hartmann A, Zeier M, Budde K, Kuypers D, Pisarski P, Le Meur Y, van der Werf M, Mamelok RD, Oellerich M, van Gelder T (2008) AcylMPAG plasma concentrations and mycophenolic acidrelated side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism. Ther Drug Monit 30:439-444